

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE 09/782,520 02/14/2001 Geraldine Lerebour 2365-28 7537 **EXAMINER** 04/19/2006 23117 7590 NIXON & VANDERHYE, PC KIM, JENNIFER M 901 NORTH GLEBE ROAD, 11TH FLOOR ART UNIT PAPER NUMBER ARLINGTON, VA 22203 1617

DATE MAILED: 04/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary Examiner	No.
Jennifer Kim Je	10
The MAILING DATE of this communication appears on the cover sheet with the correspondence address. Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAY WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status	
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAY WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAY WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status	
_	
1)⊠ Responsive to communication(s) filed on <u>30 January 2006</u> .	
The Tresponsive to continuing attention of the on obtaining 2000.	
2a)☑ This action is FINAL . 2b)☐ This action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merit	e ie
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.	, 10
Disposition of Claims	
4)⊠ Claim(s) <u>13-36</u> is/are pending in the application.	·
4a) Of the above claim(s) <u>16 and 28-36</u> is/are withdrawn from consideration.	
5) Claim(s) is/are allowed.	
6)⊠ Claim(s) <u>13-15,17-27</u> is/are rejected.	
7) Claim(s) is/are rejected.	
8) Claim(s) are subjected to.	
Application Papers	
9) The specification is objected to by the Examiner.	
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.	
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.12	1(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152	•
Priority under 35 U.S.C. § 119	
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 	
2. Certified copies of the priority documents have been received in Application No	
3. Copies of the certified copies of the priority documents have been received in this National Stage	
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	
ded the attached detailed office action for a list of the certified copies not received.	
Attachmont/o)	
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)	
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) Other:	

DETAILED ACTION

The response filed January 30, 2006 have been received.

Action Summary

The rejection of claims 13-15 and 17-27 under 35 U.S.C. 103(a) as being unpatentable over Wright (U.S.Patent No. 5,547,677) of record is being maintained for the reasons stated in the previous Office Action and the rejection is repeated in this Office Action for Applicants' convenience.

Response to Arguments

Applicants' arguments filed January 30, 2006 have been fully considered but they are not persuasive. Applicants argue that the present invention provides a method of preventing adhesion of microorganisms on the surface of the skin without the need of specific bactericidal or antimicrobial compound and the cited art requires inclusion of an antimicrobial. This not persuasive because first, Applicants claims are not drawn to a method of preventing adhesion of microorganisms on the surface of the skin without the need of specific bactericidal or antimicrobial compound, rather, it is drawn to a

method of reducing the adhesion of microorganisms to the surface of the skin without requiring the presence of antibiotic, bactericidal or fungicidal agents. Applicants' claims drawn to "without requiring" does not exclude the presence of antibiotic, bactericidal or antifungal agent because first of all the limitation is in preamble of the claims not in the body of the claim and that the composition to be employed drawn to "comprising" does not exclude the antibiotic, bactericidal or antifungal agent of the prior art, rather the presence of the antibiotic, bactericidal or antifungal agents are optional. Thus, the claims fail to patentably distinguish over the state of the art as represented by the cited references.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- Resolving the level of ordinary skill in the pertinent art. 3.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 13-15 and 17-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wright (U.S.Patent No. 5,547,677) of record.

Wright teaches an antimicrobial lipid-containing oil-in-water emulsion comprising olive oil. (abstract, column 3, lines 53-59). Wright teaches the emulsion is safe and non-toxic and can be applied to the skin. (column 1, lines 55-58). Wright teaches the emulsion can be applied topically to skin surface and mucus membranes. Wright teaches an oil-in-water emulsions have discrete droplets of oil, called the "discontinuous phase," dispersed in a "continuous phase" of water or an aqueous solvent and the discontinuous phase of Wright's emulsion binds to the biological membrane of a pathogen and subsequently solubilizes the membrane. Wright teaches the emulsion has antimicrobial activity against a broad spectrum of bacteria and several

Art Unit: 1617

yeasts. (column 1, lines 10-16). Wright teaches the emulsion can also be used for dermatological application as a cream or gel to inactivate or prevent infection secondary to *propionibacterium acnes* and prevent infection by gram positive bacteria. (column 4, lines 45-58). Wright teaches the amounts of oil (olive oil) to be employed in the emulsion is **67%** by weight. (column 4, lines 20-21).

Wright does not expressly illustrate the specific example of emulsion comprising olive oil and a disruption of the ecological balance among resident flora and the chemical characteristic of olive oil having a melting point of less than 35 C and having an interfacial tension of between 6 and 27 mN/m.

It would have been obvious to one of ordinary skill in the art to employ olive oil in the emulsion taught by Wright because Wright teach that olive oil is one of the useful oil in formulation antimicrobial oil-in water emulsion effective for inactive or prevent infection secondary to *propionibacterium acnes*. Applicant's limitation of reducing the adhesion of microorganisms to the surface of the skin and/or the mucous membrane is obvious the emulsion taught by Wright bind to the biological membrane of pathogens including *propionibacterium acnes* and subsequently solubilized the membrane. Applicant's limitation of reducing a disruption of ecological balance among resident flora is obvious because the emulsion is effective as an antimicrobial including *propionibacterium acnes*. Further, the chemical/physical characteristics of olive oil having an melting point of less than 35 C and having the specified interfacial tension can be found with the same olive oil compound and within the same amounts employed taught by Wright because the compound (olive oil) and is physical/chemical

characteristic as inseparable. One of ordinary skill in the art would have been motivated to employ olive oil comprising emulsion in order to successfully fight and reduce any bacterial contact (adhesion) by solubilizing the bacterial membrane as taught by Wright.

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.

None of the claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 5:30 am to 2 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sreenivasan Padmanabhan Supervisory Examiner Art Unit 1617

Jmk April 13, 2006